



News Release

Lonza signs manufacturing deal with IMMUNE Pharmaceuticals for Bertilimumab (iCo-008)

- **Contract covers the clinical phase 2 production of Bertilimumab (iCo-008), a human immunoglobulin monoclonal antibody under investigation for the potential treatment of several inflammatory disorders**
- **Lonza will manufacture Bertilimumab at its mammalian development facility**

Basel (Switzerland), 19 July 2011 –Lonza announced today an exclusive contract for the production of IMMUNE Pharmaceutical's human immunoglobulin monoclonal antibody, Bertilimumab, under investigation for the potential treatment of several inflammatory disorders. Under the agreement, Lonza will produce phase 2 clinical trial material at its mammalian development and manufacturing facility.

"We are excited about this opportunity to support IMMUNE Pharmaceutical's growing pipeline," said Dr. Stephan Kutzer, COO Lonza Custom Manufacturing. "This partnership is a direct reflection of our commitment to emerging pharmaceutical companies as they advance through clinical phase milestones."

Bertilimumab has great potential for the treatment of eosinophilic inflammatory bowel diseases (IBD) – Crohn's Disease and Ulcerative Colitis – and eosinophilic gastro-intestinal diseases (EGID). Bertilimumab is the first monoclonal antibody to specifically neutralize human eotaxin-1, a chemokine associated with inflammatory disease activity.

Dr. Daniel Teper, CEO of IMMUNE said, "Lonza understands the needs of emerging companies, providing assistance and flexibility, while maintaining the highest standards essential for regulatory compliance and successful partnering." IMMUNE strengthened its internal bio-manufacturing expertise by appointing to its Board of Directors, Dr David Naveh, formerly the Chief Technical Officer of Bayer Biologics Worldwide.

About Bertilimumab

Bertilimumab (also known as iCo-008 or CAT-213) is a human immunoglobulin monoclonal antibody targeting eotaxin-1, a member of the chemokine family of proteins that act as messenger molecules between the cells of the immune system. Bertilimumab has been in 126 patients in Phase 1 and 2 studies, has a good safety profile and has shown evidence of efficacy in a severe allergy indication. Bertilimumab may be indicated for inflammatory disorders including Severe Asthma, Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis) as well as ophthalmic indications (wet age related macular degeneration, vernal and atopic keratoconjunctivitis).



News Release

IMMUNE licensed worldwide rights for systemic indications from iCo Therapeutics in June 2011, while iCo is retaining the ophthalmic indications.

iCo (TSX-V:ICO) originally licensed the exclusive world-wide rights to Bertilimumab in 2006 from MedImmune Limited (formerly known as Cambridge Antibody Technology Limited), the Global Biologics Unit of AstraZeneca.

About IMMUNE Pharmaceuticals

IMMUNE Pharmaceuticals is an Israel and U.S. based biopharmaceutical company focused on the development of next generation monoclonal antibodies addressing significant unmet medical needs in the treatment of cancer and inflammatory diseases. IMMUNE Pharmaceuticals has built a robust pipeline of clinical and pre-clinical candidates based on novel targets and novel antibody technologies. For more information, visit the Company website at: www.immunepharmaceuticals.com.

About Lonza

Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries. Products and services span its customers' needs from research to final product manufacture. It is the global leader in the production and support of active pharmaceutical ingredients both chemically as well as biotechnologically. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important role in the development of novel medicines and healthcare products. In addition, Lonza is a leader in cell-based research, endotoxin detection and cell therapy manufacturing. Furthermore, the company is a leading provider of value chemical and biotech ingredients to the nutrition, hygiene, preservation, agro and personal care markets.

Lonza is headquartered in Basel, Switzerland and is listed on the SIX Swiss Exchange. In 2010, the company had sales of CHF 2.680 billion. Further information can be found at www.lonza.com.

Further information

Lonza Group Ltd
Head of Corporate Communications
Dominik Werner
Tel +41 61 316 8798
Fax +41 61 316 9798
dominik.werner@lonza.com

Lonza Group Ltd
Investor Relations
Dirk Oehlers
Tel +41 61 316 8540
Fax +41 61 316 9540
dirk.oehlers@lonza.com

Lonza Group Ltd
Media Relations
Melanie Disa
Tel +1 201 316 9413
Fax +1 201 696 3533
melanie.disa@lonza.com